Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Sunday. The brokerage issued a sell rating on the stock.

Bio-Path Price Performance

Bio-Path stock opened at $0.17 on Friday. Bio-Path has a fifty-two week low of $0.12 and a fifty-two week high of $7.67. The stock has a fifty day moving average of $0.74 and a two-hundred day moving average of $0.88.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.